Neuca SA

Neuca SA has a debt-to-equity ratio of 0.69 and a current ratio of 0.89, indicating moderate leverage and liquidity constraints. The company's free cash flow of 85.78 million PLN is significantly lower than its operating cash flow of 548.86 million PLN, primarily due to capital expenditures of 124.88 million PLN. The negative net cash position after subtracting total debt raises liquidity concerns, despite the company's medium liquidity risk rating. Profitability metrics show a return on equity (ROE) of 14.71% and a return on assets (ROA) of 2.49%. These figures are below the industry median for ROE and ROA in the Pharmaceuticals sector, suggesting that Neuca is underperforming relative to its peers in terms of asset and equity utilization. Geographically, Neuca's revenue is concentrated in Central and Eastern Europe, with no disclosed diversification into other regions. The company's operating income of 255.19 million PLN is supported by a gross profit of 1.56 billion PLN, but its net income of 155.58 million PLN reflects a relatively high cost structure. Looking ahead, Neuca's revenue is expected to grow, though the exact rate is not disclosed. The company's capital expenditures are projected to remain a drag on free cash flow, with no significant changes in the near term. The mean price target of 799.00 PLN and median price target of 770.50 PLN suggest a positive outlook from analysts, though the range from 660.00 to 995.00 PLN indicates some uncertainty. The company faces moderate liquidity risk and low dilution risk, with no immediate signs of equity dilution. However, the negative net cash position and reliance on operating cash flow to service debt could become a concern if cash flow generation weakens. Recent filings and transcripts indicate that Neuca is focused on expanding its product portfolio and maintaining market share in its core regions. The company has not disclosed any major strategic shifts or new product launches in the latest available data.